Skip to main content
Premium Trial:

Request an Annual Quote

Abbott Job Cuts Spare MDx

NEW YORK (GenomeWeb News) – Abbott plans to lay off around 700 employees as part of an ongoing restructuring, and though a couple hundred of those job cuts will come from its diagnostics business its molecular diagnostics operations will be spared, a company spokesman told GenomeWeb Daily News on Wednesday.

News of the layoffs was first reported by the Associated Press following Abbott's release of its fourth-quarter and fiscal-year 2011 financial results. Though Abbott didn't mention the cuts on its conference call Wednesday, its financial statement noted a $332 million pre-tax charge for "restructuring/integration/other."

Most of the layoffs will affect employees that manufacture vascular stents in Temecula, Calif., as well as some employees in the firm's core diagnostics business in Illinois, and pharmaceutical manufacturing, the spokesman said. He added that the cuts in the diagnostics business are a continuation of a restructuring plan begun in 2008.

Earlier Wednesday Abbott reported a 4 percent increase in its fourth-quarter revenues with profit growth of around 13 percent. Its molecular diagnostics sales rose 11 percent year over year.

Shares of Abbott closed down around 1 percent at $55.23 in Wednesday trade on the New York Stock Exchange.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.